Antibody_ID,HC_germline,CDR_H3,LC_germline,CDR_L3,Antigen_target,Neutralization,Source,Reference
CR3022,IGHV5-51,AGGSGISTPMDV,IGKV4-1,QQYYSTPYT,RBD,No,SARS_infection,Yuan et al. A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV. Science. 368:630-633.
S110,IGHV3-30,AKDRFQFARSWYGDYFDY,IGKV2-30,-,S_protein,-,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
S124,IGHV2-26,ARINTAAYDYDSTTFDI,IGKV1-39,-,RBD,-,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
S309,IGHV1-18,ARDYTRGAWFGESLIGGFDN,IGKV3-20,-,RBD,Yes,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
S315,IGHV3-7,ARDLWWNDQAHYYGMDV,IGLV3-25,-,RBD,Yes,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
S303,IGHV3-23,ARERDDIFPMGLNAFDI,IGKV1-5,-,RBD,No,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
S304,IGHV3-13,ARGDSSGYYYYFDY,IGKV1-39,-,non-RBD,Yes,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
S305,IGHV1-18,ASDYFDSSGYYHSFDY,IGKV3-11,-,non-RBD,-,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
S310,IGHV1-69,ATRTYDSSGYRPYYYGLDV,IGLV2-23,-,non-RBD,No,SARS_infection,Pinto et al. Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody. Nature. DOI: 10.1038/s41586-020-2349-y
P1A-1C7,IGHV1-46,length=15,IGKV1-39,length=10,RBD,No,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P1A-1C10,IGHV1-69,length=16,IGKV1-5,length=9,RBD,No,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P1A-1C11,IGHV1-69,length=16,IGKV1-5,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P1A-1C6,IGHV3-13,length=19,IGKV1-39,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P1A-1D3,IGHV3-13,length=18,IGKV1-39,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P1A-1C2,IGHV3-23,length=10,IGKV1-36,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P1A-1B2,IGHV3-30,length=12,IGLV2-14,length=10,RBD,No,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P1A-1C1,IGHV3-33,length=17,IGKV1D-13,length=9,RBD,No,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P1A-1D1,IGHV3-53,length=12,IGLV2-8,length=10,RBD,No,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P1A-1D5,IGHV3-53,length=15,IGKV1-33,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P1A-1D6,IGHV3-53,length=15,IGKV1-33,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2A-1A10,IGHV1-2,length=19,IGKV2-40,length=9,RBD,Yes,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1A4,IGHV1-2,length=19,IGKV2-40,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1B2,IGHV1-2,length=19,IGKV2-40,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-2G1,IGHV1-2,length=19,IGKV2-40,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-2G12,IGHV1-2,length=19,IGKV2-40,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1A10,IGHV1-2,length=19,IGKV2-40,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1B10,IGHV1-2,length=19,IGKV2-40,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1D6,IGHV1-2,length=19,IGKV2-40,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1D12,IGHV1-2,length=19,IGKV2-40,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1F10,IGHV1-2,length=19,IGKV2-40,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1F8,IGHV1-2,length=14,IGKV3-20,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-2G9,IGHV1-2,length=14,IGKV3-20,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1C3,IGHV1-46,length=15,IGKV1-5,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1C10,IGHV1-69,length=11,IGKV3-11,length=8,RBD,Yes,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-2G10,IGHV1-69,length=11,IGKV1-39,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1F11,IGHV1-69,length=17,IGLV1-40,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1D9,IGHV2-5,length=16,IGLV1-47,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1E2,IGHV2-5,length=12,IGKV1-5,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1E4,IGHV2-5,length=11,IGLV2-14,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1F4,IGHV2-70,length=14,IGLV1-44,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1A3,IGHV3-11,length=12,IGKV1-9,length=9,RBD,Yes,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1D6,IGHV3-15,length=24,IGLV1-44,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1B12,IGHV3-15,length=13,IGLV6-57,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1F9,IGHV3-15,length=16,IGKV1-NL1,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1D5,IGHV3-23,length=14,IGLV3-21,length=11,RBD,Yes,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1B4,IGHV3-30,length=22,IGKV1-39,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1F2,IGHV3-33,length=11,IGLV2-11,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-2G4,IGHV3-33,length=11,IGLV2-11,length=11,RBD,Yes,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1C8,IGHV3-33,length=13,IGKV2D-30,length=9,RBD,Yes,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2A-1B3,IGHV3-48,length=16,IGKV3-20,length=10,RBD,Yes,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1B11,IGHV3-48,length=16,IGKV3-20,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1B12,IGHV3-48,length=16,IGKV3-20,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1C4,IGHV3-48,length=16,IGKV3-20,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1E11,IGHV3-48,length=16,IGKV3-20,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-2H7,IGHV3-48,length=16,IGKV3-20,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1G12,IGHV3-48,length=16,IGKV3-20,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1E5,IGHV3-48,length=16,IGKV3-20,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1A10,IGHV3-53,length=15,IGKV1-33,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1F5,IGHV3-53,length=14,IGKV1-NL1,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1D7,IGHV3-53,length=12,IGKV2D-30,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1G1,IGHV3-66,length=11,IGKV3-20,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1E1,IGHV3-66,length=9,IGKV3-11,length=10,RBD,No,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1F11,IGHV3-66,length=11,IGKV3-20,length=8,RBD,Yes,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2A-1A8,IGHV3-9,length=23,IGLV2-14,length=10,RBD,Yes,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1B10,IGHV3-9,length=23,IGLV2-14,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1C10,IGHV3-9,length=23,IGLV2-14,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1D3,IGHV3-9,length=23,IGLV2-14,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-2H4,IGHV3-9,length=23,IGLV2-14,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1A5,IGHV3-9,length=23,IGLV2-14,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1A8,IGHV3-9,length=23,IGLV2-14,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1B1,IGHV3-9,length=23,IGLV2-14,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1C12,IGHV3-9,length=23,IGLV2-14,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1A6,IGHV3-9,length=23,IGLV2-14,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2A-1A9,IGHV3-9,length=17,IGLV1-40,length=11,RBD,Yes,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1A1,IGHV3-9,length=17,IGLV1-40,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-2G11,IGHV3-9,length=17,IGLV1-40,length=11,RBD,Yes,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1E12,IGHV3-9,length=17,IGLV3-20,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-2F6,IGHV4-38,length=20,IGLV2-8,length=10,RBD,Yes,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2A-1B10,IGHV4-39,length=20,IGLV1-47,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1B9,IGHV4-39,length=9,IGKV1-NL1,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-2F11,IGHV4-39,length=9,IGKV1-NL1,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1G8,IGHV4-39,length=11,IGKV1-5,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1A1,IGHV4-59,length=14,IGLV2-14,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1D11,IGHV4-59,length=22,IGLV3-25,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1F11,IGHV4-59,length=15,IGKV1-39,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2C-1A7,IGHV5-51,length=17,IGLV3-1,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1A12,IGHV7-4-1,length=16,IGKV1-39,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P2B-1G5,IGHV7-4-1,length=12,IGLV3-21,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P3A-1F1,IGHV3-13,length=17,IGKV1-39,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P3A-1G8,IGHV3-64,length=19,IGLV1-44,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4A-2A10,IGHV1-46,length=26,IGLV1-40,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4B-1F6,IGHV1-69,length=15,IGLV2-23,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4B-1E11,IGHV2-5,length=18,IGLV1-36,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4A-2A2,IGHV3-23,length=14,IGLV1-51,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4A-2A8,IGHV3-23,length=11,IGLV3-21,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4A-2C1,IGHV3-23,length=16,IGKV2-28,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4A-1H5,IGHV3-30,length=21,IGKV1-39,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4B-1G2,IGHV3-30,length=21,IGKV1-39,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4A-2B3,IGHV3-30,length=21,IGKV1-39,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4A-1H6,IGHV3-30,length=21,IGKV1-39,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4B-1G5,IGHV3-30,length=22,IGLV3-21,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4A-2E10,IGHV3-30,length=21,IGKV1-39,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4B-1E3,IGHV3-30,length=21,IGKV1-39,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4A-2D9,IGHV3-30,length=21,IGKV1-39,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4B-1F4,IGHV3-30,length=22,IGKV2-30,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4B-1E7,IGHV3-43D,length=20,IGKV3-1,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4B-1F10,IGHV3-7,length=13,IGKV3-21,length=12,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4A-2D1,IGHV3-9,length=13,IGKV1-12,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4A-2D2,IGHV4-39,length=16,IGKV3-20,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4B-1E12,IGHV4-59,length=11,IGLV1-44,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P4A-2C12,IGHV5-51,length=15,IGLV1-44,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P8A-1A8,IGHV3-23,length=11,IGLV3-21,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P8A-1C6,IGHV3-30,length=20,IGKV1-33,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P8A-1A5,IGHV5-51,length=18,IGLV1-47,length=12,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P8A-1D5,IGHV6-1,length=16,IGKV3-20,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1A1,IGHV1-24,length=15,IGKV2-28,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1C8,IGHV1-46,length=22,IGKV1-33,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2D5,IGHV1-46,length=24,IGLV1-40,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2C8,IGHV1-46,length=15,IGLV2-23,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2E9,IGHV1-46,length=22,IGLV2-14,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3B8,IGHV1-46,length=16,IGLV2-23,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3A11,IGHV1-69,length=14,IGKV1-39,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3C10,IGHV1-69,length=22,IGLV6-57,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1A2,IGHV1-8,length=21,IGLV1-40,length=12,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1C11,IGHV1-8,length=17,IGLV3-21,length=13,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2F11,IGHV1-8,length=15,IGKV4-1,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3B9,IGHV1-8,length=15,IGKV1-36,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2C12,IGHV2-5,length=16,IGKV3-11,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3C12,IGHV2-5,length=19,IGKV4-1,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3C3,IGHV2-5,length=12,IGLV6-57,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3C1,IGHV3-11,length=13,IGLV3-21,length=13,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1C4,IGHV3-13,length=20,IGKV1-39,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2G8,IGHV3-13,length=13,IGKV1-39,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2D3,IGHV3-13,length=16,IGKV1-39,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3B10,IGHV3-13,length=16,IGKV1-39,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1D8,IGHV3-13,length=18,IGLV3-19,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2G10,IGHV3-13,length=18,IGLV3-19,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2H6,IGHV3-15,length=18,IGLV3-19,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1D6,IGHV3-23,length=13,IGLV3-21,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2E12,IGHV3-23,length=14,IGLV3-21,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3D12,IGHV3-23,length=24,IGLV1-47,length=12,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1B6,IGHV3-30,length=20,IGKV1-33,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2E6,IGHV3-30,length=20,IGKV1-33,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1B1,IGHV3-33,length=14,IGKV3-15,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1C5,IGHV3-33,length=14,IGKV3-15,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2H7,IGHV3-33,length=14,IGKV3-15,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2G9,IGHV3-33,length=12,IGLV5-37,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2G11,IGHV3-33,length=17,IGLV2-14,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1B8,IGHV3-53,length=9,IGKV1-9,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1D2,IGHV3-53,length=15,IGLV1-40,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1D1,IGHV3-53,length=11,IGKV1-9,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2C9,IGHV3-7,length=14,IGKV3-20,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2E4,IGHV3-7,length=14,IGKV3-20,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2G12,IGHV3-7,length=12,IGLV6-57,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2D12,IGHV3-7,length=18,IGKV2-28,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2F1,IGHV3-74,length=12,IGLV6-57,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1C10,IGHV3-9,length=14,IGLV3-21,length=12,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2E8,IGHV3-9,length=13,IGLV3-21,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3A2,IGHV3-9,length=14,IGLV3-21,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2D6,IGHV3-9,length=14,IGLV1-40,length=12,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1B12,IGHV3-9,length=17,IGLV1-51,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3A6,IGHV3-9,length=27,IGLV2-14,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3D9,IGHV3-9,length=16,IGKV3-15,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1D10,IGHV3-11,length=21,IGLV2-14,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3A1,IGHV3-53,length=11,IGKV3-20,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3C8,IGHV3-53,length=11,IGKV1-9,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2D10,IGHV4-31,length=12,IGLV6-57,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2G5,IGHV4-31,length=14,IGLV3-21,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1A12,IGHV4-39,length=17,IGKV4-1,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2C7,IGHV4-39,length=16,IGLV2-23,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2F7,IGHV4-39,length=18,IGLV2-23,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2F9,IGHV4-39,length=14,IGLV2-23,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1A5,IGHV4-4,length=14,IGLV2-14,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1C6,IGHV4-4,length=22,IGLV1-40,length=12,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3A10,IGHV4-4,length=21,IGKV1-39,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1B9,IGHV4-59,length=22,IGKV4-1,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3A7,IGHV4-59,length=22,IGKV4-1,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3B1,IGHV4-59,length=22,IGKV4-1,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3B6,IGHV4-59,length=22,IGKV4-1,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2C10,IGHV4-59,length=17,IGLV3-21,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2E5,IGHV4-59,length=12,IGLV6-57,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2G4,IGHV4-59,length=12,IGKV1D-16,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2G7,IGHV4-61,length=20,IGLV2-14,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1B10,IGHV5-51,length=12,IGKV2-28,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1C9,IGHV5-51,length=11,IGLV3-19,length=12,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2D11,IGHV5-51,length=13,IGLV1-44,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3B4,IGHV5-51,length=13,IGLV1-44,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2H3,IGHV5-51,length=13,IGLV1-44,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2E1,IGHV5-51,length=12,IGLV3-21,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-1B11,IGHV7-4-1,length=20,IGKV1-39,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-2D7,IGHV7-4-1,length=10,IGKV6-21,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3C9,IGHV7-4-1,length=10,IGKV6-21,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P5A-3D11,IGHV7-4-1,length=10,IGKV6-21,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1A3,IGHV1-3,length=11,IGLV6-57,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1A8,IGHV1-46,length=20,IGLV3-21,length=13,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1B5,IGHV1-46,length=13,IGLV3-21,length=12,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1C6,IGHV1-46,length=16,IGLV3-21,length=12,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1C1,IGHV3-13,length=21,IGKV1-39,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1A5,IGHV3-33,length=15,IGKV1-33,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1A12,IGHV3-33,length=19,IGLV1-51,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1B1,IGHV3-74,length=15,IGLV1-36,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1B3,IGHV3-9,length=24,IGLV3-1,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1B12,IGHV4-34,length=16,IGLV1-51,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1B8,IGHV5-51,length=19,IGLV3-1,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1A7,IGHV7-4-1,length=14,IGLV3-21,length=12,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P16A-1A10,IGHV7-4-1,length=15,IGLV3-21,length=12,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P22A-1E10,IGHV1-46,length=15,IGKV3-11,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P22A-1D2,IGHV1-8,length=21,IGLV1-40,length=12,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P22A-1D8,IGHV3-23,length=20,IGKV3-15,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P22A-1D7,IGHV3-33,length=13,IGKV1-39,length=10,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P22A-1D1,IGHV3-53,length=11,IGKV1-9,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P22A-1E8,IGHV3-9,length=16,IGKV3-15,length=11,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P22A-1D5,IGHV4-39,length=14,IGLV2-23,length=8,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
P22A-1E6,IGHV4-59,length=16,IGKV3-20,length=9,RBD,-,SARS-2_infection,Ju et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. doi: https://doi.org/10.1038/s41586-020-2380-z
BD-494,IGHV3-53,ARDLVVYGMDV,IGKV1-9,QQLNSYPFT,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
BD-498,IGHV3-66,ARDLVVYGMDV,IGKV1-9,QQLNSYPLT,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
BD-500,IGHV3-53,ARDAMSYGMDV,IGKV1D-39,QQSYSTPPDT,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
BD-503,IGHV3-53,ARDAAVYGIDV,IGKV1D-39,QQSYTTPLFT,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
BD-504,IGHV3-66,ARDLISRGMDV,IGKV1-9,QQSYTTPLFT,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
BD-505,IGHV3-53,ARDRVVYGMDV,IGKV1D-33,HQYDNLPPT,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
BD-506,IGHV3-53,ARDLVSYGMDV,IGKV1-9,QQLNSYPLT,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
BD-507,IGHV3-53,ARDLVVYGMDV,IGKV1-9,QQLNSNPPIT,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
BD-508,IGHV3-53,ARDAQNYGMDV,IGKV1D-39,QQSYSTPPYT,RBD,Yes,SARS-2_infection,Cao et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell. doi: 10.1016/j.cell.2020.05.025
CC12.1,IGHV3-53,-,IGKV1-9,-,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.2,IGHV3-53,-,IGKV3-20,-,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.3,IGHV3-53,-,IGKV3-20,-,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.4,IGHV1-2,-,IGLV2-8,-,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.5,IGHV1-2,-,IGLV2-14,-,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.6,IGHV1-2,-,IGLV2-14,-,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.7,IGHV1-2,-,IGLV2-14,-,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.8,IGHV1-2,-,IGLV2-14,-,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.9,IGHV1-2,-,IGLV2-14,-,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.10,IGHV1-2,-,IGLV2-14,-,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.11,IGHV1-2,-,IGLV2-14,-,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.12,IGHV1-2,-,IGLV2-14,-,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.13,IGHV3-53,-,IGKV1-33,-,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.14,IGHV3-21,-,IGKV2-30,-,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.15,IGHV3-48,-,IGLV1-40,-,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.16,IGHV3-33,-,IGLV3-21,-,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.17,IGHV3-30,-,IGLV3-21,-,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.18,IGHV1-46,-,IGLV6-57,-,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.19,IGHV3-23,-,IGLV3-21,-,RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.20,IGHV3-30,-,IGLV1-47,-,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.21,IGHV1-24,-,IGLV1-44,-,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.23,IGHV4-39,-,IGLV3-25,-,non-RBD,Yes,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.24,IGHV3-30,-,IGKV1-39,-,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.25,IGHV3-23,-,IGLV1-44,-,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.26,IGHV5-51,-,IGLV7-43,-,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
CC12.27,IGHV1-2,-,IGLV2-23,-,non-RBD,No,SARS-2_infection,Rogers et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv. doi: https://doi.org/10.1101/2020.05.11.088674
COVA1-01,IGHV4-39,length=14,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-02,IGHV3-30,length=14,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-03,IGHV3-30,length=28,-,-,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-04,IGHV1-69,length=16,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-05,IGHV1-24,length=14,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-06,IGHV3-9,length=17,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-07,IGHV1-69,length=15,-,-,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-08,IGHV3-30,length=14,-,-,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-09,IGHV4-59,length=16,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-10,IGHV3-66,length=21,-,-,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-11,IGHV3-30,length=14,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-12,IGHV1-2,length=15,-,-,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-13,IGHV3-7,length=22,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-14,IGHV4-59,length=15,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-15,IGHV3-30,length=14,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-16,IGHV1-46,length=22,-,-,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-17,IGHV1-2,length=14,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-18,IGHV3-66,length=12,-,-,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-19,IGHV3-21,length=20,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-20,IGHV3-21,length=22,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-21,IGHV3-30,length=26,-,-,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-22,IGHV1-18,length=20,-,-,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-23,IGHV5-51,length=15,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-24,IGHV3-33,length=19,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-25,IGHV4-39,length=21,-,-,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-26,IGHV4-31,length=16,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA1-27,IGHV3-30,length=13,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-01,IGHV3-13,length=14,-,-,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-02,IGHV4-39,length=15,-,-,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-03,IGHV3-48,length=18,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-04,IGHV3-53,length=12,-,-,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-05,IGHV5-51,length=20,-,-,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-06,IGHV4-59,length=9,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-07,IGHV3-53,length=9,-,-,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-08,IGHV3-30,length=14,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-09,IGHV4-34,length=22,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-10,IGHV3-23,length=18,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-11,IGHV3-21,length=19,-,-,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-12,IGHV3-53,length=20,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-13,IGHV1-69,length=12,-,-,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-14,IGHV1-69,length=15,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-15,IGHV3-23,length=22,-,-,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-16,IGHV1-69,length=16,-,-,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-17,IGHV1-69,length=13,-,-,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-18,IGHV1-69,length=15,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-19,IGHV1-18,length=16,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-20,IGHV3-53,length=17,-,-,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-21,IGHV4-4,length=11,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-22,IGHV1-69,length=20,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-23,IGHV1-2,length=20,-,-,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-24,IGHV5-10,length=20,-,-,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-25,IGHV1-24,length=16,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-26,IGHV3-15,length=16,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-27,IGHV1-8,length=16,-,-,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-28,IGHV3-30,length=17,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-29,IGHV4-30,length=20,-,-,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-30,IGHV3-30,length=18,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-31,IGHV1-2,length=18,-,-,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-32,IGHV1-69,length=15,-,-,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-33,IGHV5-10,length=20,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-34,IGHV3-30,length=14,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-35,IGHV3-33,length=17,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-36,IGHV5-51,length=16,-,-,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-37,IGHV1-24,length=14,-,-,non-RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-38,IGHV4-39,length=15,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-39,IGHV3-53,length=17,-,-,RBD,Yes,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-40,IGHV4-4,length=15,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-41,IGHV3-21,length=24,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-42,IGHV4-31,length=15,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-43,IGHV1-18,length=19,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-44,IGHV3-30,length=15,-,-,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-45,IGHV1-2,length=24,-,-,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-46,IGHV4-39,length=12,-,-,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA2-47,IGHV3-9,length=21,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA3-01,IGHV4-59,length=14,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA3-02,IGHV3-7,length=14,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA3-03,IGHV3-23,length=12,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA3-04,IGHV3-33,length=22,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA3-05,IGHV1-24,length=16,-,-,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA3-06,IGHV1-69,length=18,-,-,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA3-07,IGHV3-9,length=20,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA3-08,IGHV3-9,length=16,-,-,non-RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA3-09,IGHV4-59,length=14,-,-,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
COVA3-10,IGHV5-51,length=16,-,-,RBD,No,SARS-2_infection,Brouwer et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.088716
B5,IGHV1-2,-,IGKV3-20,-,RBD,Yes,SARS-2_infection,Wu et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. DOI: 10.1126/science.abc2241
B38,IGHV3-53,AREAYGMDV,IGKV1-9,QQLNSYPPYT,RBD,Yes,SARS-2_infection,Wu et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. DOI: 10.1126/science.abc2241
H2,IGHV3-9,-,IGKV1-39,-,RBD,Yes,SARS-2_infection,Wu et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. DOI: 10.1126/science.abc2241
H4,IGHV1-2,ARVPYCSSTSCHRDWYFDL,IGKV2-40,MQRIEFPLT,RBD,Yes,SARS-2_infection,Wu et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. DOI: 10.1126/science.abc2241
COV21.1,IGHV1-58,AAPHCSGGSCLDAFDI,IGKV3-20,QQYGSSPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. bioRxiv. doi: https://doi.org/10.1101/2020.05.13.092619
COV21.2,IGHV1-58,AAPHCSGGSCYDAFDI,IGKV3-20,QQYGSSPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. bioRxiv. doi: https://doi.org/10.1101/2020.05.13.092619
COV57.1,IGHV1-58,AANHCSGGSCYDGFDI,IGKV3-20,QQYGSSPWM,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. bioRxiv. doi: https://doi.org/10.1101/2020.05.13.092619
COV57.2,IGHV1-58,AAPYCSGGSCNDAFDI,IGKV3-20,QQYGSSPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. bioRxiv. doi: https://doi.org/10.1101/2020.05.13.092619
COV107.1,IGHV1-58,AAPHCSSTSCFDAFDI,IGKV3-20,QQYGNSPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. bioRxiv. doi: https://doi.org/10.1101/2020.05.13.092619
COV107.2,IGHV1-58,AAPYCSGGSCSDAFDI,IGKV3-20,QQYGSSPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. bioRxiv. doi: https://doi.org/10.1101/2020.05.13.092619
COV21.3,IGHV3-30,ARDGIVDTAMVTWFDY,IGKV1-39,QQSYSTPPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. bioRxiv. doi: https://doi.org/10.1101/2020.05.13.092619
COV21.4,IGHV3-30,ARDQGMATTYWFDY,IGKV1-39,QQSYNTPPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. bioRxiv. doi: https://doi.org/10.1101/2020.05.13.092619
COV72.1,IGHV3-30,ARDGIVDTALVTWFDY,IGKV1-39,QQSYSTPPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. bioRxiv. doi: https://doi.org/10.1101/2020.05.13.092619
COV72.2,IGHV3-30,ARDSDVDTSMVTWFDY,IGKV1-39,QQSYSTPPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. bioRxiv. doi: https://doi.org/10.1101/2020.05.13.092619
COV72.3,IGHV3-30,ARDSDVDTAMVTWFDY,IGKV1-39,QQSYSTPPWT,RBD,-,SARS-2_infection,Robbiani et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. bioRxiv. doi: https://doi.org/10.1101/2020.05.13.092619
1M-1D2,IGHV3-64,ARGAEYYDFWSGYYSAYFDY,IGLV1-47,SMGAQPDLCA,RBD,Yes,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-13A3,IGHV3-30,ARGGGSYYYWFDP,IGKV4-1,QQYYST,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-13D11,IGHV4-34,ARAGYSSSWYGVRGVDP,IGKV3-20,QQYGSSRSWT,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-14B2,IGHV3-30,AKGSDIVVVPVGNWFDP,IGKV1-39,QQSYSTFTLYT,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-10B11,IGHV3-66,ARATWLRGVMDV,IGLV6-57,QSYDSSNHWV,RBD,No,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-14E4,IGHV4-61,ARVQRYYPDSSGFYGRRFDI,IGKV1-39,QQSHSFPFT,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-14E5,IGHV3-30,ARSGGGSYRGPFDY,IGKV1-9,QQLNSYVT,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-2D4,IGHV3-23,AKIGLGLGGLLRRYFDY,IGKV3-11,QQRTNWPL,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-2G12,IGHV3-11,DANYDYVVAQTGYGR,IGKV1-39,QQNYSTWT,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-4G4,IGHV1-46,ARERGDSSGYYEIITTANRRFGMDV,IGLV2-23,CSYAVSSTWV,RBD,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-2D1,IGHV4-39,ARGDRIQLWLLDAFDI,IGLV1-47,CSTGAQPEWLG,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-7E9,IGHV1-69,ARIPGWDRGTDRNWNDD,IGKV3-11,QQRSNWPPAFT,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-8E7,IGHV1-69,ARTYSFDSSGYYYDY,IGKV3-11,QQHSNWPPKIT,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-8H10,IGHV3-30,ARAFYDSNWSVGSYFDS,IGKV4-1,QQYYNNQWT,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-9F10,IGHV3-9,AKDSVRREYTHARVPFDN,IGKV1-39,QQSFVSPRT,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-9H1,IGHV3-30,AKSSKIFYLGESREVDY,IGKV1-17,LQHKSYPLT,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
2M-12D7,IGHV3-9,AKDVRYCSSTSCYFSAFDI,IGKV1-39,QQSYSTPRT,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0304-2F8,IGHV5-51,ARRGDGLYYYGMDV,IGKV2-28,MQALQTPQT,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0304-3H3,IGHV4-59,ARDRIAPVGKFFGWYFDL,IGKV3-15,QQYNKWPPWT,S2,Yes,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0304-4A2,IGHV4-39,ARELFTAVAGKGGIDY,IGKV4-1,HQYYNTPRT,S1,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0304-4A10,IGHV3-64,ARSSSRGFDY,IGKV4-1,QQYYSSPYA,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0317-A1,IGHV3-30,AKDFKGGSSSWYTPEIEYGMDV,IGKV3-11,QQRSNWPPT,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0317-A2,IGHV7-4-1,ARLIRHEAHTYCSGGSCYSPDYYYGMDV,IGKV1-39,QQSYSTPPT,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0317-A3,IGHV3-48,ASNPPLGEPYFDI,IGKV1-39,QQTYRPPWT,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0317-A7,IGHV3-30-3,ARWGGGMQYLDV,IGKV2-28,MQTLQTPYT,S1,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0317-A8,IGHV7-4-1,ARAGPNYDFWSGYYQTFDY,IGKV1-33,QQYDNLPLT,S1,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0317-A9,IGHV1-24,ATATAMDGYYYYYGMDV,IGKV2-24,MQATQFPYT,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0317-B1,IGHV5-51,ASAGSSWYGDAFDI,IGKV4-1,QQYYSTYGS,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0317-C4,IGHV1-24,ATATIFGVANNWFDP,IGLV1-51,GTWDSSLSVVV,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
0317-C9,IGHV3-30,AKDLGYYDILTGQLGGYYYYYGMDV,IGLV1-44,AAWDDSLNGVV,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
4A8,IGHV1-24,ATSTAVAGTPDLFDYYYGMDV,IGKV2-24,TQATQFPYT,NTD,Yes,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
9A1,IGHV3-30,AKVSAIFWLGQGLSPIDV,IGKV3-15,HQYSKWPVT,S2,No,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
8D2,IGHV3-7,ARDWDYDILTGSWFGAFDI,IGKV1-17,LQHNSYPLT,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
8D9,IGHV3-7,ARPTIGYSYGSDY,IGLV3-1,QAWDSSTGV,S2,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
10C10,IGHV3-7,ARDWDYDILTGSWFGAFDI,IGKV1-17,LQHNNYPLT,S_protein,-,SARS-2_infection,Chi et al. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv. doi: https://doi.org/10.1101/2020.05.08.083964
CV1,IGHV4-38-2,-,IGLV1-44,-,non-RBD,Yes,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV2,IGHV3-30,-,IGKV3-15,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV3,IGHV7-4-1,-,IGKV1-39,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV4,IGHV3-30,-,IGKV1-5,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV5,IGHV1-46,-,IGKV4-1,-,RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV7,IGHV3-30,-,IGKV1-5,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV8,IGHV1-18,-,IGKV3-20,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV9,IGHV4-39,-,IGLV2-14,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV10,IGHV4-59,-,IGKV3-20,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV11,IGHV4-31,-,IGKV3-11,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV12,IGHV3-30,-,IGKV2-30,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV13,IGHV7-4-1,-,IGKV1-39,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV15,IGHV3-7,-,IGLV2-11,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV16,IGHV5-51,-,IGKV3-20,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV17,IGHV1-2,-,IGLV2-23,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV18,IGHV1-24,-,IGLV1-51,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV19,IGHV1-2,-,IGKV3-20,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV21,IGHV3-15,-,IGKV3-11,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV22,IGHV3-21,-,IGLV4-69,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV23,IGHV1-3,-,IGLV3-25,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV24,IGHV1-24,-,IGLV1-51,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV25,IGHV4-30-4,-,IGKV3-15,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV26,IGHV3-30-3,-,IGKV1-17,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV27,IGHV3-30,-,IGLV2-14,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV30,IGHV3-53,-,IGKV3-20,-,RBD,Yes,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV31,IGHV1-24,-,IGLV1-51,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV32,IGHV1-2,-,IGLV1-51,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV33,IGHV1-18,-,IGLV1-40,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV34,IGHV3-30-3,-,IGLV3-12,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV35,IGHV4-38,-,IGLV1-44,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV36,IGHV1-2,-,IGLV3-25,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV37,IGHV1-18,-,IGKV1-33,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV38,IGHV3-30,-,IGKV3-11,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV39,IGHV3-30,-,IGKV2-30,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV40,IGHV1-18,-,IGKV1-17,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV41,IGHV3-30,-,IGKV3-15,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV42,IGHV1-18,-,IGKV1-39,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV43,IGHV3-30,-,IGLV6-57,-,RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV44,IGHV1-46,-,IGLV3-25,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV45,IGHV1-18,-,IGLV1-40,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV46,IGHV3-30,-,IGKV2-30,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV47,IGHV1-18,-,IGKV1-17,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV48,IGHV1-69,-,IGKV2-30,-,non-RBD,No,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CV50,IGHV3-33,-,IGLV3-10,-,non-RBD,-,SARS-2_infection,Seydoux et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv. doi: https://doi.org/10.1101/2020.05.12.091298
CA1,IGHV1-18,AREGYCSGGSCYSGYYYYYGMDV,IGKV3-11,QQRRNWGT,RBD,Yes,SARS-2_infection,Shi et al. A human neutralizing antibody targets the receptor binding site of SARS-CoV-2. Nature. DOI: https://doi.org/10.1038/s41586-020-2381-y
CB6,IGHV3-66,ARVLPMYGDYLDY,IGKV1-39,QQSYSTPPEYT,RBD,Yes,SARS-2_infection,Shi et al. A human neutralizing antibody targets the receptor binding site of SARS-CoV-2. Nature. DOI: https://doi.org/10.1038/s41586-020-2381-y
515-1,-,ARDFISRPRGYR,-,-,RBD,Yes,SARS-2_infection,Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
505-5,-,ARDFISRPRGYR,-,-,RBD,Yes,SARS-2_infection,Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
413-2,-,ARDNNYRNYYYYMDV,-,-,non-RBD,Yes,SARS-2_infection,Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
414-2,-,ARESRDYYDSSGLASRYFDL,-,-,RBD,No,SARS-2_infection,Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
553-49,-,AKDSSSWYNYYGMDV,-,-,RBD,Yes,SARS-2_infection,Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
505-3,-,ARDFISRPRGYR,-,-,RBD,Yes,SARS-2_infection,Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
553-15,-,ARVWYYYGPRDY,-,-,RBD,Yes,SARS-2_infection,Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
105-38,-,ARVQWLRGEFDY,-,-,RBD,No,SARS-2_infection,Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
415-5,-,ARAVYYYDSSGYPYAEDYFDY,-,-,RBD,No,SARS-2_infection,Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
553-20,-,ATAPVRRLGWFDP,-,-,RBD,No,SARS-2_infection,Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
105-9,-,TRDPWGTTYFDY,-,-,RBD,No,SARS-2_infection,Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
553-63,-,ARMEAPKLTLDP,-,-,RBD,Yes,SARS-2_infection,Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
414-1,-,ARGALGCSSTSCYPNNFDY,-,-,RBD,Yes,SARS-2_infection,Wan et al. Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection. bioRxiv. doi: https://doi.org/10.1101/2020.05.19.104117
C105,IGHV3-53,-,IGKV1-9,-,RBD,Yes,SARS-2_infection,Barnes et al. Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies. doi: https://doi.org/10.1101/2020.05.28.121533